Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
PR NewswireApr 19, 2024
SEOUL, South Korea, April 19, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection. "The fundamental way to deal with Dengue fever is taking the antiviral drug, which is effective on all four serotypes of the Dengue virus, in the early stage of virus infection," CEO Oh said. "To win eme